Natalizumab does not have the cost-benefit of others

Manzano CL, Sadek A, Cooper C, Tomlinson E, Wang H, Rice C, Tallantyre E, Rao-Middleton A, Whiting P, Thom H. Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. Health Technol Assess. 2026;30:1-290. Background: Multiple sclerosis is an immune-mediated…